Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
27 hedge funds and large institutions have $13M invested in Marinus Pharmaceuticals, Inc in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
165% more capital invested
Capital invested by funds: $4.9M → $13M (+$8.07M)
17% more funds holding
Funds holding: 23 → 27 (+4)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
+$1.07M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.04M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$627K |
| 4 |
Jennison Associates
New York
|
+$524K |
| 5 |
BlackRock
New York
|
+$316K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
-$67.9K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$63.4K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$17K |
| 4 |
Squarepoint
New York
|
-$13K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$12.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$11K | -2,712 | Closed |
|
|
NFG
27
Next Financial Group
Houston,
Texas
| – | -$3K | -668 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| – | +$5 | +1 | New |
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$672 | +125 | New |
|
MRNS Hedge Fund Activity: Q1 2017 in Review
27 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2017, worth a combined $13M — up 165% from $4.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MRNS positions and 3 closed out — a net gain of 7 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Nexthera Capital, opening a new position worth an estimated $1.07M. The largest seller was Creative Planning, cutting an estimated $67.9K.
- 27 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2017, up from 23 in Q4 2016.
- Funds reported $13M of Marinus Pharmaceuticals, Inc stock for Q1 2017, up 165% quarter-over-quarter.
- 10 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2017 and 3 closed out, a net change of +7 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q1 2017 was Nexthera Capital, an estimated $1.07M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2017 was Creative Planning, an estimated $67.9K sold.
Based on aggregated 13F filings for Q1 2017.